No price history available.
Key financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | IDRm | 297,216 | 210,528 | 360,183 | 418,529 | 431,605 | 401,536 | N/A | N/A |
| Operating profit | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | IDRm | -203,215 | -149,736 | -42,427 | -31,928 | -4,462 | -27,797 | N/A | N/A |
| EPS reported | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
PT Martina Berto Tbk, along with its affiliated entities, specializes in the creation and commercialization of beauty and personal care items, as well as traditional herbal remedies, catering to markets both within Indonesia and internationally. The company's operations are divided into two main areas: cosmetics and herbal products. Its extensive range of cosmetic offerings includes liquid formulations such as facial cleansers, moisturizers, toners, foundations, body colognes, and hair styling sprays; dry cosmetic products like eye shadows, blush-ons, and various loose or compact powders; and semi-solid items including lipsticks and creamy foundations. Within the herbal segment, PT Martina Berto manufactures products such as traditional facial masks, exfoliating body scrubs, and an assortment of herbal teas. Beyond direct manufacturing, the company also actively promotes and trades its beauty and herbal medicine lines. Furthermore, it serves as a contract manufacturer, producing private label dry, semi-solid, liquid, and aerosol cosmetics for other brands. Products reach consumers through a variety of distribution channels, including online platforms, major retail chains, supermarkets, wholesalers, specialized cosmetic stores, beauty salons, and spas. These offerings are marketed under established brands like Cempaka, Martina, Pesona, Biokos Martha Tilaar, Caring Colours Martha Tilaar, and Belia Martha Tilaar. Founded in 1977, PT Martina Berto Tbk maintains its headquarters in Jakarta, Indonesia, and operates as a subsidiary of PT Mathana Megahayu Inti.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PT Martina Berto Tbk (MBTO.JK)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
PT Martina Berto Tbk, along with its affiliated entities, specializes in the creation and commercialization of beauty and personal care items, as well as traditional herbal remedies, catering to markets both within Indonesia and internationally. The company's operations are divided into two main areas: cosmetics and herbal products. Its extensive range of cosmetic offerings includes liquid formulations such as facial cleansers, moisturizers, toners, foundations, body colognes, and hair styling sprays; dry cosmetic products like eye shadows, blush-ons, and various loose or compact powders; and semi-solid items including lipsticks and creamy foundations. Within the herbal segment, PT Martina Berto manufactures products such as traditional facial masks, exfoliating body scrubs, and an assortment of herbal teas. Beyond direct manufacturing, the company also actively promotes and trades its beauty and herbal medicine lines. Furthermore, it serves as a contract manufacturer, producing private label dry, semi-solid, liquid, and aerosol cosmetics for other brands. Products reach consumers through a variety of distribution channels, including online platforms, major retail chains, supermarkets, wholesalers, specialized cosmetic stores, beauty salons, and spas. These offerings are marketed under established brands like Cempaka, Martina, Pesona, Biokos Martha Tilaar, Caring Colours Martha Tilaar, and Belia Martha Tilaar. Founded in 1977, PT Martina Berto Tbk maintains its headquarters in Jakarta, Indonesia, and operates as a subsidiary of PT Mathana Megahayu Inti.
